Smartwatch Tracking of Hot Flashes in Prostate Cancer Patients
This study, called Prostate 007, is looking at whether men with prostate cancer who experience hot flashes (vasomotor symptoms) from their hormone therapy (Androgen Deprivation Therapy or ADT) can consistently use a smartwatch to track these symptoms. We want to see how well the information they log on the smartwatch matches up with daily surveys about their hot flashes. Participants will wear a smartwatch for 4 weeks and press a button on it when they have a hot flash. They will also complete daily surveys sent via text message. The study aims to enroll 18 men aged 18 or older who have prostate cancer and are currently receiving ADT.
- Study design
- This is an interventional study with a planned enrollment of 18 male participants. It is not specified if it is randomized or blinded.
- What's involved
- You would wear a smartwatch continuously for 4 weeks, logging hot flashes by pressing a button. You would also complete daily electronic surveys about your hot flashes.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured at 28 days, indicating the study duration for data collection.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael Devitt, MD · PRINCIPAL_INVESTIGATOR · University of Virginia
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Duration of wear per day28 days
For each participant, we will calculate the duration of device wear for each day using the real-time data recorded by the device and estimate the mean daily duration.
- Percent of days with self-reported time marked vasomotor events28 days
Percent of days with self-reported time marked vasomotor events, using the real-time marked vasomotor events from the device.
- Concordance between time marked vasomotor events and events described through EMAs.28 days
Concordance between time marked vasomotor events and EMA reporting of vasomotor events during the corresponding time period.